AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01624740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Rate Stimulation
Description: Stimulation was given at a rate of 1200 Hz.
Study NCT02815904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Mother Care
Description: Providing skin to skin human touch
Study NCT01753037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone (DHEA)
Description: DHEA 130 mg administered orally for 5 days.
Study NCT01753037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
Study NCT03551730 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Enoxaparin
Study NCT03551730 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Enoxaparin
Study NCT03551730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04207086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study NCT04207086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
Study NCT01765556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: multiple doses of ketoconazole in Period B and C
Study NCT01765556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: single dose of vemurafenib in Period A and C
Study NCT03179683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser application
Description: an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
Study NCT03418883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Study NCT03418883 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mirror therapy
Study NCT01692158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin, Low-Molecular-Weight
Description: single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Study NCT01692158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Study NCT01016652 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A multifocal contact lens
Description: low-add multifocal contact lens
Study NCT02747134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation and Mindfulness skills
Study NCT02747134 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Regulation and Mindfulness skills
Study NCT02999555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovum pickup
Description: Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
Study NCT01924832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: tablet
Study NCT05074004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
Study NCT02739009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106 single ascending doses, intravenous
Study NCT02739009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single ascending doses, intravenous
Study NCT01921439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Feedback
Description: Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
Study NCT03627481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Description: Endoscopic sinus surgery for nasal polyposis
Study NCT01140880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
Study NCT01140880 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Truvada
Description: Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
Study NCT02549898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
Study NCT02549898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol will be applied to provoke migraine attacks in migraineurs
Study NCT02549898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USPIO-MRI
Description: USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
Study NCT02549898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBI-MRI
Description: Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
Study NCT00910871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
Study NCT00910871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Regimen (BR) for MDR-TB
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
Study NCT01132378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
Study NCT00652496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01% ophthalmic solution
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Study NCT00652496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.015% formulation 1 ophthalmic solution
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Study NCT00652496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.015% formulation 2 ophthalmic solution
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Study NCT00652496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.02% ophthalmic solution
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
Study NCT00652496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost 0.03% ophthalmic solution
Description: Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
Study NCT00472056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300 mg/m\^2 IV for 1 Day
Study NCT02836808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAIPaDi
Description: Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
Study NCT03886818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressings
Description: Standard dressings will be used from surgery to wound healing
Study NCT03886818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO strategy
Description: The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
Study NCT00472056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
Study NCT00472056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
Study NCT00472056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 IV x 1 Day
Study NCT00472056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.
Study NCT01395706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG Fluorescence technique
Description: This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated
Study NCT03802513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: Individualized physiotherapy including exercises to be performed by the Veteran at home.
Study NCT04038034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10- MINIACTIVES
Description: COQUN oral formulation 100 mg BID
Study NCT04038034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02218671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WE 941 OD tablets
Study NCT01803789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Kirschner Wire
Study NCT02739009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106 multiple ascending doses, intravenous
Study NCT02739009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple intravenous administrations
Study NCT01016652 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A Contact Lens
Description: standard sphere contact lens
Study NCT03438123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CZT SPECT imaging
Description: Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
Study NCT02202226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Study NCT02202226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01981486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: BID modified-release tablets
Study NCT01981486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999 Tablets
Description: BID modified-release tablets (20 to 240 mg BID)
Study NCT01674478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microlipid with fish oil
Description: Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
Study NCT02333344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5mg
Description: two-year Zoledronic acid 5mg infusion treatment
Study NCT00863356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2009-I-Epistaxis-1
Description: Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
Study NCT04608370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active tPBM session
Description: In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
Study NCT04608370 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham tPBM session
Description: In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
Study NCT03847324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
Study NCT01803789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Kirschner Wire
Study NCT03027999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tight nursing follow-up
Description: In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~1. a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~2. A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP > 2.7
Study NCT03847324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physiotherapy
Description: This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.
Study NCT03847324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
Study NCT03847324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
Study NCT00847262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temisartan
Description: Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
Study NCT00847262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
Study NCT02941302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detecting of Biological Borders of Gliomas
Description: Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
Study NCT03252587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT00187122 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: See Detailed Description section for description of treatment plan.
Study NCT00187122 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation Therapy
Description: See Detailed Description section for description of treatment plan.
Study NCT03252587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT01674478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microlipid
Description: A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
Study NCT00511576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGCD0103 & Docetaxel
Description: In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks.
Study NCT01595295 — intervention group
Intervention type: OTHER
Intervention: non interventional
Study NCT03905200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3D-speckle tracking imaging
Description: The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
Study NCT02167074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25G FNA needle
Study NCT02167074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20G ProCore FNB needle
Study NCT02540018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries
Description: Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied.
Study NCT02540018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter
Description: Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
Study NCT03725683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Increased caliber balloon
Description: Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events.
Study NCT03725683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: matched caliber balloon
Description: Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events.
Study NCT02942251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical features and medication
Description: This group will be suggested to take optimize treatment according to Chinese treatment guidelines.